Valuation : Assembly Biosciences, Inc.

Market Cap 620M 533M 503M 458M 857M 59.29B 865M 5.99B 2.31B 30.08B 2.33B 2.28B 95.53B P/E 2026 *
-261x
P/E 2027 * -11.2x
Enterprise Value 534M 459M 433M 395M 737M 51.03B 744M 5.16B 1.98B 25.88B 2B 1.96B 82.21B EV / Sales 2026 *
8.41x
EV / Sales 2027 * 14.5x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
1 day-7.33%
1 week-15.69%
Current month-9.43%
1 month+13.91%
3 months+36.84%
6 months+2.91%
Current year-10.44%
1 week 30.34
Extreme 30.34
36.68
1 month 26.74
Extreme 26.735
37.01
Current year 21.8
Extreme 21.795
37.01
1 year 20.23
Extreme 20.23
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
42.6
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 2022-12-31
Director of Finance/CFO - 2025-06-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 2026-06-03
Director/Board Member 61 2017-12-13
Director/Board Member 68 2019-08-05
Date Insider Type Main position Quantity % Market Cap. Importance
6/4/26 Free

Director

8,000 0.0514%
6/4/26 Free

Director

8,000 0.0514%
6/4/26 Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-7.33%-15.69%+36.84%+163.04% 669M
-0.56%-8.08%-3.88%+10.58% 46.38B
-2.08%-3.57%+402.72%+533.09% 44.51B
+0.12%-5.27%+39.94%+20.50% 42.3B
-2.62%-5.76%+8.88%+77.44% 39.91B
-1.26%-3.37%+11.87%+40.55% 32.79B
+0.16%-3.65% - - 17.13B
-0.54%-1.72%+22.34%+115.10% 16.36B
-0.03%-3.46%+12.68%+30.90% 14.31B
-1.92%-6.94%+78.12%+36.68% 13.29B
Average -1.61%-3.24%+67.72%+114.21% 26.77B
Weighted average by Cap. -1.11%-3.78%+86.97%+129.45%

Financials

2026 *2027 *
Net sales 63.43M 54.55M 51.47M 46.89M 87.65M 6.06B 88.45M 613M 236M 3.08B 238M 233M 9.77B 34.12M 29.34M 27.69M 25.22M 47.15M 3.26B 47.58M 330M 127M 1.65B 128M 125M 5.26B
Net income 1.4M 1.21M 1.14M 1.04M 1.94M 134M 1.96M 13.56M 5.22M 68.05M 5.27M 5.15M 216M -56.83M -48.88M -46.12M -42.01M -78.54M -5.43B -79.25M -549M -211M -2.76B -213M -209M -8.75B
Net Debt -86.48M -74.38M -70.17M -63.93M -120M -8.27B -121M -836M -322M -4.19B -325M -318M -13.32B -127M -109M -103M -93.79M -175M -12.13B -177M -1.23B -472M -6.15B -476M -466M -19.54B
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
26-09-10 US$30.46 -7.33% 348,620
26-09-09 US$32.87 -6.83% 724,817
26-09-08 US$35.28 -3.61% 227,771
26-09-04 US$36.60 +1.30% 156,451
26-09-03 US$36.13 -1.61% 224,976
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
30.46USD
Average target price
52.00USD
Spread / Average Target
+70.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!